---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-118969"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:59:44.103121+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BiomX discontinues Phase 2b CF trial of BX004, cuts workforce, explores strategic alternatives

## Summary
- Independent DMC had recommended continuing Study with adjusted dosing, but company cites insufficient resources to execute alternative strategy.
- Significant workforce reduction being implemented as part of cost-cutting measures.
- BiomX will focus on advancing BX011 for diabetic foot infections, subject to financial resource availability.
- Company is reviewing strategic alternatives to maximize shareholder value.

## SEC filing metadata
- accession: 0001213900-25-118969
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025118969/0001213900-25-118969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025118969/ea0268807-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-118969
- JSON: https://secwatch.observer/filing/0001213900-25-118969.json
- Plain text: https://secwatch.observer/filing/0001213900-25-118969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.